DB ups Alcon to 'buy', sees growth from product innovations

Alcon AG

20/01/2026 09:24

** Deutsche Bank upgrades Swiss eye care company Alcon ALCC.S to "buy" from "hold", citing near-term growth prospects driven by innovation

** The broker expects organic sales growth to reaccelerate in 2026, driven by a series of new product launches such as the Unity surgical efficiency platform and Tryptyr medication for dry eyes

** DB points to "particularly unique" innovation period and projects an increase in profitability in the coming year

** The broker says Alcon's promising growth potential for H1 2026 makes the company stand out from its competitors and sees 25% potential upside from the current share price

** Out of 15 analysts covering Alcon, eleven rate the company "strong buy" or "buy", two "hold" and two "sell" - LSEG data

 (Reporting by Simon Ferdinand Eibach)

 ((Simonferdinand.eibach@thomsonreuters.com))